Showing 1 - 20 results of 341 for search '(( brain ((web decrease) OR (((teer decrease) OR (mean decrease)))) ) OR ( _ parp decrease ))', query time: 0.48s Refine Results
  1. 1
  2. 2
  3. 3

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    “…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …”
  4. 4
  5. 5
  6. 6

    Claudin V is decreased following infection with Mtb. by Amanda S. Latham (12093638)

    Published 2024
    “…Exposure to Mtb H37Rv and HN878 decreased claudin V expression compared to uninfected controls in the frontal cortex (E), cerebral nuclei (J), brain stem (O), thalamus (T), and hippocampus (Y). …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Astrocytes increase contact with vessels and expression of AQP4 following Mtb infection, which is decreased in cytosis<sup>+</sup> animals. by Amanda S. Latham (12093638)

    Published 2024
    “…Decreased expression of AQP4, and endfoot contact, is found in cytosis<sup>+</sup> animals in the frontal cortex (D and E), cerebral nuclei (J and K), brain stem (P and Q), thalamus (V and W) and hippocampus (BB and CC). …”
  17. 17

    PARP9 knockdown promotes apoptosis and DNA damage. by Yating Li (1819822)

    Published 2024
    “…(E) DNA damage in GC cells significantly increased post-PARP9 knockdown as determined by comet assay. (F) The anti-DNA damage capacity of GC cells decreased markedly following reduction of PARP9 expression. …”
  18. 18
  19. 19
  20. 20

    Data Sheet 1_Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.pdf by Maria Delgado-Ortet (8840702)

    Published 2025
    “…In this work, we developed noninvasive imagingbased measurements of spatial and longitudinal heterogeneity in a retrospective analysis of a phase 2 non-randomized study of germline BRCA1/BRCA2 mutated (gBRCAm) ovarian cancer patients treated with combination of PARP inhibitors (PARPi) and immune checkpoint inhibitors (ICIs).…”